Identification and validation of volatile organic compounds as predictive biomarkers for the efficiency of immunotherapy as treatment for malignant pleural mesothelioma. University of Antwerp
Malignant pleural mesothelioma (MPM) is an aggressive cancer of the pleural lining of the thoracic cavity, mainly caused by historical asbestos exposure. MPM is characterised by a long latency period (30-50 years) between initial asbestos exposure and diagnosis; the latter often delayed due to nonspecific symptoms which manifest at advanced stage. This delay leaves patients with a poor prognosis, with a median survival of 9-11 months. In recent ...